TRIDOPA levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; carmellose sodium; hyprolose; sodium sulfate; magnesium stearate; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LEVODOPA-CARBIDOPA CR TABLET (EXTENDED-RELEASE) Kanada - Inggris - Health Canada

levodopa-carbidopa cr tablet (extended-release)

pharmascience inc - levodopa; carbidopa - tablet (extended-release) - 100mg; 25mg - levodopa 100mg; carbidopa 25mg - dopamine precursors

LEVODOPA-CARBIDOPA CR TABLET (EXTENDED-RELEASE) Kanada - Inggris - Health Canada

levodopa-carbidopa cr tablet (extended-release)

pharmascience inc - levodopa; carbidopa - tablet (extended-release) - 200mg; 50mg - levodopa 200mg; carbidopa 50mg - dopamine precursors

CARLEVENT levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium sulfate; hyprolose; carmellose sodium; microcrystalline cellulose; magnesium stearate; trehalose dihydrate; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: powdered cellulose; microcrystalline cellulose; sodium sulfate; carmellose sodium; magnesium stearate; hyprolose; trehalose dihydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 175 mg; carbidopa monohydrate, quantity: 47.2 mg (equivalent: carbidopa, qty 43.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 150 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; iron oxide red; carmoisine aluminium lake - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 125 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; allura red ac aluminium lake; carmine - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.